Lunsekimig

芦塞奇米单抗

Report date: 2026/05/25 20:02:40

Base Information

Drug NameLunsekimig
Drug Alias NameSAR-443765
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)
Mechanisms of ActionAnti-IL13Thymic stromal lymphopoietin inhibitors
TargetsInterleukin-13Thymic stromal lymphopoietin
Therapy Area/IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)InflammationDermatitis, Atopic +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[36] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesVetter Development Services Austria GmbhSanofiSanofi-Aventis Deutschland Gmbh +[5] 
Inactive CompaniesN/A
Active IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)InflammationDermatitis, Atopic +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A